Evaluation of the diagnostic performance of laboratory-based c-reactive protein as a triage test for active pulmonary tuberculosis. by Samuels, Thomas HA et al.
RESEARCH ARTICLE
Evaluation of the diagnostic performance of
laboratory-based c-reactive protein as a triage
test for active pulmonary tuberculosis
Thomas H. A. SamuelsID
1,2☯¤a, Romain Wyss3☯, Stefano Ongarello3, David A.
J. MooreID
1,2, Samuel G. Schumacher3‡*, Claudia M. Denkinger3¤b‡
1 London School of Hygiene and Tropical Medicine, London, United Kingdom, 2 Hospital for Tropical
Diseases, University College London Hospitals NHS Foundation Trust, London, United Kingdom,
3 Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland
☯ These authors contributed equally to this work.
¤a Current address: University College London Hospitals NHS Foundation Trust, London, United Kingdom
¤b Current address: Division of Tropical Medicine, University of Heidelberg, Heidelberg, Germany




A highly sensitive triage test that captures most symptomatic patients at increased likelihood
of having pulmonary tuberculosis (PTB) would ‘rule-out’ lower-risk patients from expensive
confirmatory testing. Although studies have assessed the diagnostic accuracy of a C-reac-
tive protein (CRP) triage test for PTB in HIV+ patients, limited data are available from HIV-
cohorts.
Materials and methods
In this retrospective case-control study, 765 serum samples were selected from FIND’s bio-
bank. Each sample had been collected from an adult presenting with respiratory symptom-
atology to district hospitals in South Africa and referral hospitals in Cambodia, Peru,
Georgia and Vietnam between 2007–2017. Serum CRP measurements were obtained
using a laboratory-based assay. CRP cutoff-points of�8mg/L and�10mg/L were prede-
fined as a positive triage test result. The PTB reference standard was two contemporane-
ously collected sputum liquid culture results.
Results
CRP demonstrated an overall sensitivity for PTB of 79.8% (95%CI 75.5–83.5) and 77.7%
(95%CI 73.4–81.6) for cutoff-points of 8mg/L and 10mg/L respectively. Specificity was
62.8% (95%CI 57.8–67.6%) and 66.6% (95%CI 61.1–70.7) respectively. Area-under-the-
curve using Receiver Operating Characteristic analysis was 0.77 (95%CI 0.74–0.81).
Threshold analysis showed optimal CRP cutoff-points were higher in HIV+ than HIV- partici-
pants. An algorithm in which CRP triage was followed by confirmatory Xpert MTB/Rif testing
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achieved a sensitivity of 75.1% (95%CI 69.0–80.4%) whilst decreasing Xpert usage by
40.6%.
Discussion
CRP may not meet the challenge of a catch-all TB triage test. However, it shows promise in
HIV+ individuals. Further research is required in a prospective study using point-of-care plat-
forms to further evaluate its capabilities.
Introduction
New diagnostic approaches are urgently needed to reduce tuberculosis (TB) incidence and
meet WHO End TB targets [1]. The Xpert MTB/Rif assay (hereafter referred to as ‘Xpert’) is
more sensitive than smear microscopy, faster than traditional culture methods and has been
rolled out in many settings throughout the world [2, 3]. However, placement of the instrument
at primary care level in low resource settings where the majority of individuals with TB first
access care is restricted by its infrastructure requirements and cost [4–6]. Efforts are being
made to develop Xpert platforms suited to the available infrastructure, but the cost of testing
all people undergoing evaluation for presumed-TB remains prohibitive.
Currently, two weeks of cough is widely used as a prompt to initiate diagnostic testing for
pulmonary TB (PTB). However, TB prevalence amongst these individuals is low [7]. Interest
has therefore grown in the usage of a two-stage diagnostic algorithm in which a highly sensi-
tive first triage test, applied to patients with symptoms of active pulmonary TB and deployed at
the peripheral reaches of the healthcare system, effectively captures most subjects at higher
likelihood of having TB. This triage test should also have sufficient specificity to enable ‘rule-
out’ from the expensive second stage of testing for those at very low likelihood, creating signifi-
cant resource savings especially in medium prevalence settings. The target product profile
(TPP) suggested by the World Health Organization (WHO) for such a triage test specifies a
minimum sensitivity of 90% and specificity of 70% against the confirmatory test for PTB [8].
C-reactive protein (CRP) is an attractive candidate as a triage test for TB. Many point-of-
care (POC) CRP tests are commercially available with some costing less than US$1 [9], and
this blood-based biomarker has shown promise in the diagnosis of subjects undergoing evalua-
tion for TB. A recent meta-analysis has shown that CRP has a high sensitivity (93%) and mod-
erate specificity (60%) amongst outpatients with PTB symptoms in high-burden settings, with
data primarily coming from studies in people living with HIV [10]. Also, it has been shown to
be an effective screening test for HIV+ patients and could reduce the number of Xpert tests
required without comprising diagnostic yield over symptom-based screening [11, 12]. In con-
trast, the evaluation of the performance of CRP as a triage test has been less well-studied. A
recent meta-analysis of diagnostic accuracy studies found CRP to perform with an overall sen-
sitivity and specificity of 89% and 57% respectively for pulmonary TB, showing significant var-
iation by geography, HIV status and clinical setting [13]. CRP was not deployed as a triage test
in any of the included studies. However, several studies in HIV+ South African patients in
which CRP has been used as a triage test demonstrated similar performance [14, 15]. To our
knowledge no dedicated studies have done so in HIV- patients. Individuals who present to
healthcare with symptoms suggestive of PTB are likely to have a greater burden of pyogenic
infections and non-TB inflammatory conditions than populations being screened, which may
negatively affect specificity compared with studies evaluating CRP in this context [10].
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Although some studies have assessed the diagnostic accuracy of CRP in TB, no study has
yet assessed the suitability of CRP for use as a triage test for individuals undergoing evaluation
for presumed TB independent of HIV status in representative high endemic countries. In this
study, we aimed to assess the diagnostic accuracy of quantitative laboratory-based CRP as a tri-
age test for the detection of active TB in bio-banked serum samples taken from individuals
with presumed TB presenting to secondary care across five high-burden TB countries.
Materials and methods
Ethics statement
All study-related activities were approved by the Human Research Ethics Committees (HREC)
of the partners in-countries. These were: University of Cape Town, South Africa; Universidad
Peruana Cayetano Heredia, Peru; Pham Ngoc Thach Hospital, Vietnam; Calmette Hospital,
Cambodia; National Centre for Tuberculosis and Lung Diseases, Georgia.
Study population
For this retrospective nested case-control study, serum samples were selected from FIND’s
biorepository. These samples were previously collected from adults presenting at district hos-
pitals in South Africa and referral hospitals in Cambodia, Peru, Georgia and Vietnam between
2007 and 2017. Participants were included if age was greater to or equal to 18 years, if they
were able to give informed consent and had presented with symptoms suggestive of pulmo-
nary TB. Symptoms were specified as current cough, haemoptysis, recent weight loss, night
sweats and fever. To be included in the analysis all participants had to provide both a blood
sample and at least 2 sputum samples at enrolment prior to initiation of anti-tuberculous ther-
apy. Blood samples were preserved in temperature-controlled freezers at -80˚C from collection
until CRP testing. Participants were excluded if they had received anti-tuberculous therapy
within 60 days prior to enrolment.
The study followed a nested case-control design. Cases were individuals with TB and con-
trols were individuals presenting with symptoms that warranted investigation and for whom
sputum testing proved negative for M.tb. The cases and controls were chosen to reflect the geo-
graphic distribution, age and sex of participants across the entire cohort and were weighted to
have at least 20% smear-negative results among culture-positive TB patients at each site and at
least 25% of HIV+ patients overall. Cases and controls were matched by HIV status. All study-
related activities were approved by the Human Research Ethics Committees of the partners in-
countries. Written informed consent was obtained from patients, as per study protocol (proto-
col and consent form available upon request). Study participation did not affect standard of
care. Reporting followed STARD guidelines [16].
Index test
Serum CRP levels were measured using the Multigent CRP Vario assay (a latex immunoassay)
on Abbott Architect C8000 at Quest laboratories. For testing, in brief, the stored serum was
thawed and then processed and interpreted, following the manufacturer’s protocol.
Reference testing
All sputum samples were processed using standardized protocols in centralized accredited lab-
oratories of the partner institutions. The testing flow for the samples is available in the study
protocol (S1 File). Testing was performed on all available sputum specimens and included
smear fluorescence microscopy with Auramine staining, MGIT liquid culture (Becton
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Dickinson, Franklin Lakes, USA) and solid culture on Löwenstein-Jensen (LJ) medium. The
presence of M.tb complex in solid and liquid culture was confirmed with MPT64 antigen
detection and/or the MTBDRplus line probe assays (both Hain Lifesciences, Nehren, Ger-
many). Xpert MTB/Rif (‘Xpert’, Cepheid, Sunnyvale, USA) was performed on sputum samples
from 2011 onwards when it was available, following the manufacturer’s protocol. The opera-
tors of the index were blinded to the results of the reference standard.
Definitions
A CRP cutoff-point of�8mg/L or�10mg/L was predefined as a positive triage test. These val-
ues were chosen based on previous work [10, 11]. To obtain the best estimate of performance
of CRP, a comparison was made against a microbiological reference standard (MRS). For this
MRS, participants were assigned to two diagnostic categories using a combination of labora-
tory and clinical findings. Cases (TBpos) included patients with any culture positive for M.tb.
Controls (TBneg) were patients with negative microscopy, cultures and Xpert tests (when
available) for M.tb (and at least one non-contaminated culture result), who were not started on
anti-TB treatment and were alive and improved at 8-weeks follow-up. Participants who did
not fulfil these criteria were excluded from selection into the study. In order to evaluate CRP
against the most likely confirmatory test available in low-and middle-income country (LMIC)
settings, participants were classified based on a single sputum Xpert result (Xpert reference
standard; XRS). Participants with an indeterminate Xpert result were excluded from the XRS.
All classification of participants was done prior to performing the index test.
Sample size calculation
391 cases and 374 controls were sufficient to achieve a total 95% confidence interval (95%CI)
width of<10% based on the targeted performances of the index test (a sensitivity of 90% and a
specificity of 70% as per the minimum target product profile specified by the WHO). 212 HIV
+ individuals were selected amongst these, 111 cases and 101 controls, achieving a total 95%CI
width of 11% for sensitivity and 23% for specificity for HIV+ participants based on the same
targeted test performance.
Statistics
For descriptive statistics, dichotomous variables were reported as numbers with percentages
whilst continuous variables either as median with an inter-quartile range (IQR) if non-
parametric or mean with a standard deviation (SD) if normally-distributed. The primary out-
come was the overall estimates of sensitivity and specificity of CRP in the diagnosis of TB
based on the MRS. Secondarily, we compared CRP against the Xpert reference standard.
Results were reported for pre-defined CRP cutoff-points as point estimates with 95%CI calcu-
lated using Wilson’s method [17]. An analysis of the following sub-groups was prespecified:
smear status, HIV status, number of symptoms (categorized as< = 1, 2–3 or > 3). Analyses by
region and gender were post-hoc based-on data trends. Receiver Operating Curve (ROC) anal-
ysis was undertaken to explore the performance of alternative CRP thresholds. Post-hoc, opti-
mal cutoff-points were selected using a manual data inspection approach. The total combined
sensitivity and specificity deficit relative to the minimum TPP was calculated for all cutoff-
points along the ROC curve. The optimal cutoff-point was defined as that with the lowest com-
bined deficit. A log-scale linear multivariable regression model of the effect of a pre-defined
selection of variables on CRP concentration was generated. Variables were selected for the
multivariable model if the p-value was less than 0.1 in univariate analysis (see Supporting
Information). Akaike information criterion (AIC) was used to build the best model. Log
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transformation of CRP concentration was used to achieve normal distribution of residuals. A
complete case analysis was used. The relationship between CRP concentration and time-to-
sputum culture positivity was explored using LOWESS and Pearson’s correlation coefficient.
All analyses were performed using STATA 15 (StataCorp, USA). An analysis plan was prede-
fined and is available upon request.
Results
Participants
Of the 765 participants included in the study, 307 (40.1%) were female and the median age was
36 (IQR 27–47) (Table 1). Xpert results were available for 527/765 (68.9%) participants. Partic-
ipants were drawn from five countries, with the majority being from Peru, South Africa and
Vietnam (87.6% of the total). HIV status was available for 96.7% of participants, of which
28.8% were seropositive. HIV seropositivity differed markedly between study sites, ranging
from 0% (Georgia and Cambodia) to 63.7% (South Africa). CD4 counts were available for
44.6% of HIV+ participants, with a median count of 202 (IQR 76–444).
The vast majority of patients presented with cough. Night sweats, fever and haemoptysis
were seen more frequently in TBpos participants, and frequently co-existed (S2 Fig). Thirty
percent of participants presented with 4 or more symptoms, two-thirds of whom had TB.
Distribution of CRP
CRP varied significantly by TB status (Fig 1): the median CRP for TBpos participants was
47.1mg/L (IQR 12.3–93.0mg/L), and 4.25mg/L (IQR 1.3–19.1mg/L) for TBneg participants with a
mean difference 41.3mg/L (95%CI 33.4–49.2mg/L). Similarly, CRP results were significantly
higher in smear-positive TBpos participants compared to smear-negatives (median of 55.3mg/L
(IQR 20.5–106.3mg/L) vs 18.7mg/L (IQR 2.2–59.3mg/L) p<0.001). Furthermore, median CRP
concentration increased with the number of symptoms participants reported at presentation and
was higher in HIV positive participants than HIV negative. Higher CRP concentrations were
associated with shorter time to culture positivity, a proxy of mycobacterial load (S3 Fig).
The results of the multivariable regression are shown in Table 2. As expected from the CRP
distribution shown in Fig 1, positive TB status and a positive smear microscopy result, as well
as an increased number of symptoms at presentation, remained strongly associated with
higher CRP results. Higher CRP results were also seen in HIV+ (p<0.001).
Receiver Operating Characteristic (ROC) curve analysis
Fig 2A shows the ROC curve for data using the MRS. Area under the curve (AUC) equalled 0.77
(95%CI 0.74–0.81). CRP did not meet TPP at any cutoff-point. The CRP cutoff-point with the
closest diagnostic performance to TPP was 12mg/L (sensitivity 76.0% (95%CI 71.5–79.9%), speci-
ficity 69.5% (95%CI 64.7–74.0%)). Fig 2B shows the ROC curve using the XRS. AUC equalled
0.83 (95%CI 0.79–0.87). However, CRP still did not meet the TPP at any cutoff-point using the
XRS. A cutoff of 18mg/L gave a diagnostic performance closest to the TPP (sensitivity 84.7% (95%
CI 78.8–89.2%), specificity 69.5% (95%CI 64.4–74.1%)). The effect of varying the CRP cutoff-
point on diagnostic performance against the MRS and XRS is shown in the S3 and S5 Tables.
Sensitivity and specificity analysis
At a cutoff-point of 8mg/L, CRP concentrations were elevated in 451/765 participants includ-
ing 312/391 participants with culture-confirmed TB. This corresponded to a sensitivity of
79.8% (95%CI 75.5–83.5). Using a cutoff-point of 10mg/L CRP concentrations were found to
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be elevated in 431/765 participants, including 304 with culture-confirmed TB, corresponding
to a sensitivity of 77.7% (95%CI 73.4–81.6). The corresponding specificity was 62.8% (95%CI
57.8–67.6) using an 8mg/L cutoff-point and 66.6% (95%CI 61.1–70.7) using 10mg/L (Table 3).
Against the XRS, CRP showed an overall sensitivity of 90.7% (95%CI 85.6–94.1) and a specific-
ity of 57.3% (95%CI 52.0–62.4) at the 8mg/L cutoff-point (S2 Table). At a 10mg/L cutoff-point
this was 89.6% (95%CI 84.4–93.3) and 60.8% (95%CI 55.5–65.8) respectively.
Table 1. Participant characteristics.
Participant Characteristics N (total participants = 765)
TBpos (n = 391) TBneg (n = 374)
Age Median (IQR) 33 (25–43) 39 (31–54)
Sex Female (%) 125 (32.0) 182 (48.7)
Male (%) 266 (68.0) 192 (51.3)
Site of Study Cambodia (%) 30 (7.7) 18 (4.8)
Georgia (%) 30 (7.7) 17 (4.5)
Peru (%) 125 (32.0) 138 (36.9)
South Africa (%) 70 (17.9) 70 (18.7)
Viet Nam (%) 136 (34.8) 131 (35.0)
Smear status S+C+ (% of TB cases) 289 (73.9)
S-C+ (% of TB cases) 102 (26.1)
HIV status Positive (% of participants with known HIV status) 111 (28.8) 102 (28.7)
Negative (% of participants with known HIV status) 274 (71.2) 253 (71.3)
Unknown (% of total) 6 (1.5) 19 (5.1)
CD4 Count <200 (% with CD4 count) 29 (61.7) 18 (37.5)
> = 200 (% with CD4 count) 18 (38.3) 30 (62.5)
Unknown (% of HIV+ participants) 64 (57.7) 54 (52.9)
Median CD4 count (IQR) 128 (71–357) 279 (106–515)
History of BCG Positive history of vaccination or scar present (%) 209 (53.5) 206 (55.1)
Negative history of vaccination (%) 78 (19.9) 83 (22.2)
Unknown history of vaccination and scar indeterminate (%) 74 (18.9) 68 (18.2)
Not obtained (%) 30 (7.7) 17 (4.5)
Prior history of TB Positive (%) 75 (19.2) 96 (25.7)
Negative (%) 312 (79.8) 275 (73.5)
Unknown (%) 4 (1.0) 3 (0.8)
QuantiFERON result Positive (% with result) 72 (73.5) 0 (0)
Negative (% with result) 20 (20.4) 120 (85.1)
Indeterminate (% with result) 6 (6.1) 21 (14.9)
Not obtained (% total participants) 293 (74.9) 233 (62.3)
Number of symptoms at presentation 1 (%) 41 (10) 118 (32)
2–3 (%) 195 (50) 183 (49)
4+ (%) 155 (40) 73 (19)
Symptoms at presentation Cough (%) 387 (99) 363 (97)
Haemoptysis (%) 88 (23) 37 (10)
Fever (%) 237 (61) 169 (45)
Night Sweats (%) 227 (58) 144 (39)
Recent weight loss (%) 142 (36) 164 (44)
GeneXpert MTB/Rif status (n = 527) Xpert+ (%) 183 (83) 0 (0)
Xpert- (%) 38 (17) 306 (100)
https://doi.org/10.1371/journal.pone.0254002.t001
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Subgroup analyses
Diagnostic performance against the MRS was analysed for pre-specified sub-groups (Table 3).
CRP became more sensitive but less specific as the number of symptoms at presentation
increased. It showed greater sensitivity for smear-positive over smear-negative TB (86.2%
(95%CI 81.7–89.7%) vs. 61.8% (95%CI 52.1–70.6%) at a cutoff-point of 8mg/L). CRP was
highly sensitive for TB in HIV+ participants, showing a sensitivity of 93.7% (95%CI 87.6–
96.9%) and 91.9% (95%CI 85.3–95.7%) at cutoff-points of 8mg/L and 10mg/L respectively
(Table 3). However, specificity was suboptimal at 49.0% (95%CI 39.5–58.6%) and 52.9% (95%
CI 43.3–62.3%) respectively. By contrast, in HIV- participants CRP was less sensitive but was
markedly more specific, with a sensitivity of 74.8% (95%CI 69.4–79.6%) and specificity of
Fig 1. The distribution of CRP amongst all study participants (n = 765). A) by TB and smear status; B) by TB status
and number of symptoms at presentation; C) by TB and HIV status. Lavender line demarcates a CRP threshold of
8mg/L–subjects below this line would not go forward for further testing in a triage-based algorithm. Gold lines
demarcate median and inter-quartile range. TBneg = tuberculosis negative by MRS. TBpos = tuberculosis positive by
MRS. HIV = human immunodeficiency virus. CRP = C-reactive protein.
https://doi.org/10.1371/journal.pone.0254002.g001
Table 2. Log-scale linear regression model of the effect of shown variables on CRP concentration.
Variable Log median fold-change in CRP (from reference) 95% Conf. Interval P value
Lower Upper
TB status TBpos 2.12 1.51 2.94 <0.001
TBneg Reference
Smear microscopy result Smear+ 2.60 1.85 3.67 <0.001
Smear- Reference
HIV status HIV+ 2.06 1.62 2.61 <0.001
HIV- Reference
Number of symptoms at presentation 4+ 4.46 3.22 6.18 <0.001
2–3 2.09 1.57 2.78 <0.001
1 Reference
n = 735 Prob > F: <0.0001 AIC = 2661 R-squared = 0.3817
https://doi.org/10.1371/journal.pone.0254002.t002
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68.0% (95%CI 62–73.4%) at a cutoff-point of 8mg/L, and 72.6% (95%CI 67.1–77.6%) and
71.1% (95%CI 65.3–76.4%) at a cutoff-point of 10mg/L respectively.
The optimal cutoff-point was markedly different in HIV+ and HIV- participants, although
the difference in the AUC between these two populations was not significant. For HIV-
Fig 2. Receiver Operating Characteristic (ROC) curves demonstrating the performance of CRP in the diagnosis of PTB. A) ROC curve against culture; B) ROC curve
against Xpert MTB/Rif. The shaded orange area represents the sensitivity and specificity combinations that meet at least the minimum target of one of the Target Product
Profile characteristics. Minimum (Sensitivity 90% Specificity 70%) and Optimal (Sensitivity 95% Specificity 80%) Target Product Profile targets are plotted. Pre-defined
CRP cutoff-points are plotted as red circles and yellow squares with optimal CRP cutoff-points plotted as green diamonds; all have estimated performance stated.
AUC = Area Under Curve; TPP = Target Product Profile; PTB = Pulmonary tuberculosis.
https://doi.org/10.1371/journal.pone.0254002.g002
Table 3. Sensitivity and specificity of CRP in the diagnosis of culture-positive tuberculosis.
Variable (n/N) CRP�8mg/L CRP�10mg/L AUC (95%CI)
Sensitivity (95%CI) Specificity (95%CI) Sensitivity (95%CI) Specificity (95%CI)
Overall (391/765) 79.8 (75.5–83.5) 62.8 (57.8–67.6) 77.7 (73.4–81.6) 66.0 (61.1–70.7) 0.77 (0.74–0.81)
Smear Status
(289/663) Smear + (Culture+) 86.2 (81.7–89.7) 62.8 (57.8–67.6) 84.4 (79.8–88.2) 66.0 (61.1–70.7) 0.82 (0.79–0.85)
(102/476) Smear—(Culture+) 61.8 (52.1–70.6) 62.8 (57.8–67.6) 58.8 (49.1–67.9) 66.0 (61.1–70.7) 0.63 (0.57–0.70)
HIV status
(111/213) Positive 93.7 (87.6–96.9) 49.0 (39.5–58.6) 91.9 (85.3–95.7) 52.9 (43.3–62.3) 0.83 (0.78–0.89)
(274/527) Negative 74.8 (69.4–79.6) 68.0 (62.0–73.4) 72.6 (67.1–77.6) 71.1 (65.3–76.4) 0.76 (0.72–0.81)
Number of presenting symptoms
(41/159) 1 symptom 43.9 (29.9–59.0) 78.8 (70.6–85.2) 34.1 (21.6–49.5) 81.4 (73.4–87.4) 0.61 (0.51–0.71)
(195/378) 2–3 symptom 76.4 (70.0–81.1) 62.8 (55.6–69.5) 75.4 (68.9–80.9) 66.1 (59.0–72.6) 0.76 (0.71–0.81)
(155/228) 4+ symptom 93.5 (88.5–96.5) 37.0 (26.8–48.5) 92.5 (87.0–95.5) 41.1 (30.5–52.6) 0.77 (0.70–0.84)
N = total number of cases and controls, n = number of TBpos cases as defined by the MRS. Smear-positive (n = 289) and smear-negative (n = 102) participants were
each assessed against all TBneg (n = 374) participants, giving a total of 663 and 476 included participants respectively.
https://doi.org/10.1371/journal.pone.0254002.t003
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participants a CRP cutoff-point of 6mg/L gave a sensitivity of 78.5% (95%CI 73.2–82.9%) and
a specificity of 64.4% (95%CI 58.4–70.1%), whilst in HIV+ participants a cutoff-point of
22.7mg/L gave a sensitivity of 85.6% (95%CI 77.9–90.9%) and a specificity of 69.6% (95%CI
60.1–77.7%)). Sub-analyses by country of origin are reported in the supporting information,
along with analyses using the XRS (S2 and S4 Tables). Sensitivity and specificity showed a
large degree of heterogeneity between study sites, although the number of participants at some
sites were small.
CRP triage algorithm
A realistic implementation scenario for CRP triage testing would involve an algorithm in
which a positive CRP triage result led to a confirmatory Xpert MTB/Rif test. Given such a sce-
nario, the number of required confirmatory tests would be decreased by 40.6% using a CRP
cutoff-point of 8mg/L. However, 55/221 TBpos participants with determinate Xpert results
(24.9%) would be missed. By contrast, if Xpert MTB/Rif were implemented for all without
CRP triage, 38 (17.2%) participants would be missed. Further details are provided in S6 Table.
Discussion
Currently, CRP is the only available inexpensive POC-compatible investigation with the
potential to be a suitable triage test for tuberculosis. This study for the first time provides an
assessment of the performance of a quantitative laboratory-based CRP test for the diagnosis of
presumed TB in patients presenting across five high-burden TB countries independent of HIV
status [14, 15]. Whilst the specificity against culture-defined TB was close to 70%, sensitivity
was sub-optimal at 77.7% at a cutoff-point of 10mg/L. For Xpert-defined TB CRP sensitivity
was 90.7% and thus met the sensitivity as defined in WHO Triage-TPP but fell 13 percentage
points short of the specificity of the TPP at 8mg/L. Cutoff-points of 8mg/L and 10mg/L were
selected on the basis of previous work [10, 11] but the optimal cutoff-point seems to occur at
higher CRP concentrations. Considering the most likely implementation scenario with Xpert
as a confirmatory test (as indicated in the TPP), 18mg/L would be the best cutoff-point in our
dataset for a triage test. Whilst the use of CRP as a triage test would reduce usage of confirma-
tory Xpert testing by about 40% at a cutoff-point of 8mg/L, the results suggest it would lead to
approximately a quarter of culture-positive cases being missed, 8 percentage points more in
absolute terms than with an Xpert-for-all strategy.
CRP concentrations tended to be higher in individuals with more symptoms at presenta-
tion and those with smear-positive disease, and it performed with greater sensitivity in these
patient groups. In addition, higher CRP at presentation was associated with a shorter time to
culture positivity, confirming previous findings [11]. As smear-positive TB cases likely con-
tribute as much as 80% of total disease transmission [18], and as an effective POC triage test
would likely lead to the consideration of TB in more patients, it is possible that despite subopti-
mal diagnostic performance, CRP could still contribute to the reduction of TB disease burden
compared with current practice and to the rational use of Xpert cartridges. However, the sub-
optimal specificity might make the implementation of the test in an Xpert-algorithm challeng-
ing, especially in low prevalence settings. An algorithm that considers clinical risk factors in
addition, or sequential testing [19], could be considered.
An algorithmic approach using CRP to triage individuals to confirmatory Xpert testing
shows promise. Over half of culture-positive cases that would have been missed by this algo-
rithmic approach were missed Xpert diagnoses, not a result of CRP test performance (S1 Fig).
Of note, Xpert MTB/Rif was 82.8% sensitive for culture-positive TB in this study, lower than
reported in meta-analyses [20, 21]. Xpert Ultra is likely to become the predominant TB test on
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the Xpert platform and is shown to have improved sensitivity over Xpert MTB/Rif [22]. The
transition to Ultra could lead to algorithm sensitivity gains, although would likely result in
some decrease in specificity. Reducing Xpert cartridge consumption using an algorithmic
approach would have important financial implications in low-income settings. Furthermore,
in conjunction with the advent of smaller, more portable and robust Xpert platforms designed
for use in LMIC community settings [23, 24], POC CRP testing in an algorithmic approach
may provide an opportunity to increase test coverage at the location that the majority of TB
patients initially access care [4], and could increase diagnostic pick-up. However, this study
used laboratory-based methods to quantify CRP and the performance of any algorithm would
need to be confirmed using POC-testing platforms to assess suitability for the field. Perfor-
mance of field-based POC clinical tests vary widely, and so this would not be an insignificant
translational barrier.
Although CRP did not meet the TPP overall, use of alternate cutoff-points based on HIV
sero-status allowed for improved performance in HIV+ participants. This suggests that CRP at
one defined cutoff-point might not meet the challenge of being a catch-all triage test for the
global TB epidemic, but different cutoff-points might be necessary in high and low HIV-preva-
lence settings. Whilst CRP had excellent sensitivity in HIV+ participants at the pre-defined
cutoff-points, specificity was far lower than in HIV- participants. The latter is likely to reflect
one or both of the increased prevalence of infective pathologies or the baseline CRP found in
HIV+ patients [25–28]. Using a higher CRP cutoff-point for HIV+ participants improved
specificity, almost meeting TPP using the XRS. Recent studies have suggested CRP has a role
in TB screening of HIV+ individuals [11, 12]. This study supports previous work suggesting it
could also have a role in triaging HIV+ patients undergoing evaluation for presumed TB, with
CRP cutoff-points adjusted accordingly [14, 15]. Indeed, the WHO advocates HIV testing
whenever TB is presumed [29] and mandatory POC HIV testing to inform CRP cutoff-point
adjustment could assist in further operationalising HIV screening within TB programs.
Despite concerns that the diagnostic specificity in HIV- participants would be compromised
by the burden of alternative pyogenic and inflammatory conditions, the specificity of CRP for
culture-positive TB in HIV negative participants was satisfactory. The suboptimal sensitivity
seen in this patient group may be due to low levels of systemic immune activation at lower
bacillary burdens, as suggested by the poor performance of CRP in smear negative disease.
CRP performance varied by study site (in a post-hoc analysis reported in the supporting
information), tending to perform better outside south-east Asia. Previous data assessing the
role of CRP in the diagnosis of TB have largely been from sub-Saharan Africa [10]. CRP has
been found to better distinguish bacterial from viral illness in febrile patients in Asia compared
to those from equatorial Africa. This is likely because of the burden of malaria and parasitic
co-infection in the latter [30, 31]. However, it is likely the burden of TB/bacterial co-infection
is higher in South-East Asia [32], adversely impacting the diagnostic performance of CRP in
these settings. Furthermore, previous work by Brown et al. [33] suggests there may be intrinsic
differences in host CRP response to TB between different ethnicities and mycobacterial strain
type, raising the prospect of adjustment of CRP cutoff-points by geography in order to
improve diagnostic performance. More work is required to better understand these
observations.
This study has a number of strengths. It is the first study to explore the utility of CRP as a
triage test and reports the diagnostic characteristics of CRP at a range of cutoff-points. It used
participants from a range of study locations and with a range of mycobacterial burdens, and in
doing so is largely representative of the global TB epidemic. The use of a laboratory-based ana-
lyser allowed assessment of the sensitivity and specificity of CRP without concerns introduced
by the accuracy of POC platforms.
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However, it also has some limitations. Smear negative participants made up 26% of TB
cases in this study compared to approximately 50% generally reported in clinical practice [34].
CRP performed less well in these participants, and so overall test performance in a prospective
setting may be worse than reported here. Facilities enabling liquid sputum culture are often
not available at peripheral health centres in high-burden countries and so its use as a confirma-
tory test may be limited in these settings at present. However, Xpert could act as such a test; it
is being rapidly scaled-up in high burden countries and endorsed by the WHO as a follow-on
test for smear-negative PTB [35]. Whilst this study used laboratory-based CRP measurements,
triage testing in peripheral health centres would require a POC platform. Performance of such
platforms vary widely and would require further evaluation against a laboratory standard. Fur-
thermore, the performance of the proposed algorithm would need to be determined prospec-
tively using POC platforms in a population with more co-morbidities before any
implementation of CRP for triage could occur.
CRP may not be the catch-all triage test that the global TB epidemic requires. However, it
shows promise in certain patient groups: this study suggests a possible role in HIV+ individuals
undergoing evaluation for presumed TB. Further research is required in a prospective study
using POC-platforms to more thoroughly evaluate its capabilities in the field. Should these
studies prove its utility, and in conjunction with the ongoing development of community-
based Xpert platforms, it raises the possibility of increasing access to TB testing in resource-
poor settings.
Supporting information
S1 Fig. Participant flow diagram for CRP cutoff-point of 8mg/L.
(TIF)
S2 Fig. Venn diagram showing distribution of TB-related symptoms in TBpos participants
on presentation to health care (n = 391). Numbers represent number of participants present-
ing with the indicated symptom complex. Total TBpos participants presenting with night
sweats n = 227, with haemoptysis n = 88, with recent weight loss n = 269 and with none of the
above n = 61.
(TIF)
S3 Fig. Scatterplot of CRP concentration against time to sputum liquid culture positivity
for TBpos participants. Blue dots represent individual CRP data points, red line demonstrates
line of best fit and green demonstrates LOWESS locally weighted smoothing. As CRP concen-
tration decreased linearly with increased time to sputum culture positivity, Pearson’s correla-
tion was applied and found to be significant with a coefficient of -0.234 (p = 0.003).
(TIF)
S4 Fig. ROC curve analysis of CRP performance in the diagnosis of tuberculosis using A) the
MRS and B) the XRS, by HIV status. The shaded orange area represents the sensitivity and
specificity combinations that meet at least the minimum target of one of the Target Product
Profile characteristics. Minimum (Sens 90% Spec 70%) and Optimal (Sens 95% Spec 80%) Tar-
get Product Profile targets are plotted as a black diamond and black triangle respectively. Pre-
defined CRP cutoff-points are plotted as red circles and yellow squares with optimal CRP cut-
off-points plotted as green diamonds. In A) optimal CRP cutoff-points occurred at 23mg/L for
HIV+ participants and 6mg/L for HIV- participants. In B), these cutoff-points were 29mg/L
(Sensitivity 90.3% Specificity 68.3%) and 11mg/L (Sensitivity 86.0% and Specificity 68.8%)
respectively. AUC = Area Under Curve; ROC = Receiver Operating Characteristic; CRP = C-
reactive protein; MRS = Microbiological reference standard; XRS+ Xpert MTB/Rif reference
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standard.
(TIF)
S5 Fig. ROC curve analysis of CRP performance in the diagnosis of tuberculosis against the
MRS by A) Age of serum sample at time of CRP analysis and B) without Vietnamese sera older
than 3,000 days. Variation by study site prompted post-hoc exploratory analysis, which
revealed CRP diagnostic performance was significantly worse in pre-2011 samples taken in
Viet Nam compared to those taken later. A significant negative correlation between CRP levels
and serum sample age was seen in Vietnamese TBpos participants, without a similar correla-
tion being observed in TBneg samples. Optimal sensitivity and specificity against MRS exclud-
ing this pre-2011 data (B) was 84.5% (95%CI 79.7–88.3) and 69.5% (95%CI 64.5–74.0)
respectively at 12mg/L cutoff-point. This also explains much of the reported difference in CRP
performance between the XRS and the MRS, as the pre-2011 Vietnamese participants did not
receive Xpert testing. The shaded orange area represents the sensitivity and specificity combi-
nations that meet at least the minimum target of one of the Target Product Profile characteris-
tics. Minimum (Sens 90% Spec 70%) and Optimal (Sens 95% Spec 80%) Target Product
Profile targets are plotted as a black diamond and a black triangle respectively. Pre-defined
CRP cutoff-points are plotted as red circles (8mg/L) and yellow squares (10mg/L) with optimal
CRP cutoff-points plotted as green diamonds. AUC = Area Under Curve; ROC = Receiver
Operating Characteristic; CRP = C-reactive protein; MRS = Microbiological Reference Stan-
dard.
(TIF)
S1 Table. Characteristics of participants who received Xpert MTB/Rif testing.
(PDF)
S2 Table. Sensitivity and specificity of CRP against the XRS by study site, smear status,
HIV status and number of symptoms at presentation. N = total number of cases and con-
trols, n = number of TBpos cases as defined by the XRS. Smear-positive (n = 289) and smear-
negative (n = 102) participants were each assessed against all TBneg (n = 374) participants, giv-
ing a total of 663 and 476 included participants respectively.
(PDF)
S3 Table. Threshold analysis of the performance of CRP against the XRS using ROC curve
data, overall and by HIV status.
(PDF)
S4 Table Sensitivity and specificity of CRP against the MRS by study site N = total number
of cases and controls, n = number of TBpos cases as defined by the MRS.
(PDF)
S5 Table. Threshold analysis of the performance of CRP against the MRS using ROC curve
data, overall and by HIV status.
(PDF)
S6 Table. The diagnostic accuracy of CRP triage against the MRS at varying CRP triage
thresholds. In this algorithm, a positive CRP triage test above the stated threshold would trig-
ger patients to move forward to confirmatory testing by the stated method. The performance
of chest X-ray (CXR) as a triage test was assessed for comparison. A CXR was defined as posi-
tive for TB if the radiographic appearance was judged to be consistent with typical or atypical
TB. The sensitivity and specificity of a single Xpert MTB/Rif against the MRS is also presented.
(PDF)
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S7 Table. Univariate linear regression analysis of the relationship between CRP and
selected variables. All variables with a p value <0.1 were considered for inclusion into multi-
variable analysis. Akaike Information Criterion values were then used to build the best model.
CD4 count was excluded from the multivariable model despite meeting significance as only 95
study participants had recorded values. AIC was not reported for CD4 count as sample size dif-
fered from other variables.
(PDF)
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